These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 23738508

  • 1. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Wang H, Mu W, Zhai J, Xing D, Miao S, Wang J, Deng Y, Wang N, Chen H, Yang H, He X, Shang H.
    Trials; 2013 Jun 05; 14():165. PubMed ID: 23738508
    [Abstract] [Full Text] [Related]

  • 2. 'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
    Tu X, Liu F, Jordan JB, Ye XF, Fu P, Wang F, Zhong S.
    Trials; 2013 Jul 18; 14():223. PubMed ID: 23866835
    [Abstract] [Full Text] [Related]

  • 3. [Network Meta-analysis of Qi-supplementing and Yin-nourishing Chinese patent medicines in treatment of early diabetic nephropathy].
    Wang WR, Zhang XM, Li JX, Yang JY, Yu RH, Xie YM.
    Zhongguo Zhong Yao Za Zhi; 2023 Jul 18; 48(14):3949-3964. PubMed ID: 37475086
    [Abstract] [Full Text] [Related]

  • 4. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM, Zhang Y, He XH, Chen HD, Wang ZF, Guo J, Wang XM, Gao ZZ, Wang JP, Liu W, Zhao LH, Tong XL.
    Trials; 2018 Mar 27; 19(1):200. PubMed ID: 29587863
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
    Kou J, Wu J, Yang HT, He YN, Fang JA, Deng YY, Xie YS, Nie LF, Lin HL, Cai GY, Chen XM.
    Trials; 2014 Dec 05; 15():479. PubMed ID: 25480673
    [Abstract] [Full Text] [Related]

  • 6. Network pharmacology combined with metabolomics to study the mechanism of Shenyan Kangfu Tablets in the treatment of diabetic nephropathy.
    Wang X, He Q, Chen Q, Xue B, Wang J, Wang T, Liu H, Chen X.
    J Ethnopharmacol; 2021 Apr 24; 270():113817. PubMed ID: 33444720
    [Abstract] [Full Text] [Related]

  • 7. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J, Wu Y, Gong X, Ma Y, Yu S, Gao J.
    Trials; 2019 Aug 07; 20(1):481. PubMed ID: 31391092
    [Abstract] [Full Text] [Related]

  • 8. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M, Wen Y, Yang L, Wu X, Lu X, Zhang B, Huang W, Li P.
    Trials; 2016 May 23; 17(1):259. PubMed ID: 27216240
    [Abstract] [Full Text] [Related]

  • 9. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.
    Nephrol Dial Transplant; 2000 Apr 23; 15(4):487-97. PubMed ID: 10727543
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial.
    Wu J, Duan SW, Yang HT, Deng YY, Li W, He YN, Ni ZH, Zhan YL, Lin S, Guo ZY, Zhu J, Fang JA, Liu XS, Wang LH, Wang R, Wang NS, Cheng XH, He LQ, Luo P, Sun SR, Sun JF, Yin AP, Jiang GR, Chen HY, Liu WH, Lin HL, Liang M, Ma L, Chen M, Song LQ, Chen J, Zhu Q, Xing CY, Li Y, Gao JN, Li RS, Li Y, Zhang H, Lu Y, Zhou QL, Fu JZ, He Q, Cai GY, Chen XM.
    J Integr Med; 2021 Mar 23; 19(2):111-119. PubMed ID: 33589406
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.
    Ann Intern Med; 2003 Apr 01; 138(7):542-9. PubMed ID: 12667024
    [Abstract] [Full Text] [Related]

  • 12. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 01; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease.
    Liao T, Zhao K, Huang Q, Tang S, Chen K, Xie C, Zhang C, Gan W.
    Medicine (Baltimore); 2020 Jul 31; 99(31):e21137. PubMed ID: 32756091
    [Abstract] [Full Text] [Related]

  • 14. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R, Wei F, Qu L, Bai L, Li J, Li F, Yan W, Wang Q, Wei J.
    Trials; 2020 Nov 23; 21(1):951. PubMed ID: 33228726
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.
    PLoS One; 2015 Nov 23; 10(5):e0126027. PubMed ID: 25938778
    [Abstract] [Full Text] [Related]

  • 16. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    J Am Soc Nephrol; 2005 Mar 23; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [Abstract] [Full Text] [Related]

  • 17. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
    Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL.
    Trials; 2019 Dec 21; 20(1):756. PubMed ID: 31864393
    [Abstract] [Full Text] [Related]

  • 18. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.
    Am J Kidney Dis; 2012 Dec 21; 60(6):896-903. PubMed ID: 22770926
    [Abstract] [Full Text] [Related]

  • 19. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
    Salcedo-Alejos M, Banda-Espinoza F, Rodríguez-Morán M, Guerrero-Romero F.
    Nephrol Dial Transplant; 2005 Oct 21; 20(10):2120-5. PubMed ID: 16091379
    [Abstract] [Full Text] [Related]

  • 20. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.